Ocugen pays $15 mn upfront to Bharat Biotech for Covaxin rights in Canada
The Hindu
Similar to the US arrangement, Ocugen will retain 45 per cent of the profit from sales of Covaxin in Canada.
Ocugen Inc, the US partner for has announced the payment of $15 million upfront to the Indian drug maker for extending the vaccine rights to Canada. Ocugen in a regulatory filing said it has agreed to pay another $10 million to Bharat Biotech within a month from the commercial launch of Covaxin in the North American country. Also read:More Related News

Scaling Artificial Intelligence(AI) at the speed at which consultants project is not possible by the laws of physics and may not be environmentally sustainable, said Tanvir Khan, who is the Executive Vice President and Chief Operating Officer of NTT DATA North America, part of the Japanese technology services and data centre company NTT Data, in an interview with The Hindu.












